The Breast Oncology Program at the Susan F. Smith Center for Women's Cancers at Dana-Farber provides state-of-the-art and compassionate care for breast cancer patients. Our breast cancer clinicians are committed to providing your patients with the best and most individualized treatment options available, including the latest medical oncology, surgical options, breast reconstruction, and radiation therapy.
Our focused and specialized services include programs for: young adults with breast cancer, metastatic breast cancer, inflammatory breast cancer, breast cancer during pregnancy, breast and ovarian cancer genetics and prevention, older adults with breast cancer, patients with breast cancer brain metastases, breast cancer in men, and ductal carcinoma in situ (DCIS).
Featured Content |view more
Mind and Body: Prioritizing Mental Health
A lump felt in the shower. Weight loss. Night sweats. The anticipation — refreshing the portal for results, awaiting a phone call, wondering if your life will change in an instant.
Can Metastatic Breast Cancer Be Cured?
When Yvonne Fantaci discovered she had breast cancer at age 60, it had already spread to her lungs, liver, and elsewhere. Fantaci felt blindsided. She was otherwise completely healthy. She never expected such a shocking diagnosis.
Ann Partridge, MD, MPH Presents PROs from the COMET Study
Patients with low-risk DCIS who underwent active monitoring had comparable physical, emotional, and psychological outcomes to patients who received standard treatment, according to results from the phase 3 COMET trial data.
Judy Garber, MD, MPH Presents Updated Results of the OlympiA Study
Dana-Farber’s Judy Garber, MD, MPH shared updated results from the phase 3 OlympiA study. The new analysis provides further support for olaparib’s benefits in patients with high-risk, HER2-negative breast cancer with germline mutations in BRCA1 or BRCA2.
Antonio Giordano, MD, PhD Discusses Novel CDK4-Selective Inhibitor
Dana-Farber's Antonia Giordano, MD, PhD shares new data on a novel CDK4-selective inhibitor in como with letrozole as 1st line treatment in HR+/HER2 Metastatic Breast Cancer.
Jennifer Ligibel, MD Discusses Weigh Loss Intervention
Dana-Farber's Jennifer Ligibel, MD reviews a telephone-based weight loss intervention that led to significant improvements in metabolic and inflammatory biomarkers associated with cancer recurrence according to new data.